Sign in
Active, not recruitingNo phase

Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy

Key facts

Who runs it
Centre Hospitalier Universitaire, Amiens
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
200 people, planned
Started
14 Jan 2025
Ended
Aug 2025
Type of study
Observational
Record updated
19 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age : > 18 years old
  • Uveitis requiring immunosuppressive therapy
  • Including at least one posterior involvement according to the SUN terminology: posterior, or intermediate and posterior, or anterior and posterior, or panuveitis

Who cannot take part

  • Ocular involvement in Behcet's disease requiring biologic therapy as first-line immunosuppressive treatment
  • Uveitis associated with multiple sclerosis or systemic lupus erythematosus
  • Uveitis without posterior segment involvement
  • Infectious uveitis
  • Patients objecting to the use of their personal data for research purposes

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Uveitis is an inflammatory disease of the uvea, constituting the 4th leading cause of legal blindness worldwide and the 3rd leading cause of avoidable blindness . It is not a rare condition, with an incidence of 17 to 52 per 100,000 population and a prevalence of 38 to 204 per 100,000 population. In the case of cortico-dependence, it is generally accepted to propose sparing with a conventional immunosuppressant, whose efficacy is estimated at around 70%, compared with biotherapies, which are considered more effective (over 90%) but only available as 2nd-line treatment. However, there are few studies on the failure factors of this first-line treatment, such as macular thickness , gender, or vitamin D deficiency. Risk factors for flare-ups are nevertheless known, notably ethnicity, and smoking. The aim of this study is to identify risk factors for treatment failure after three months of first-line immunosuppressive therapy in patients with chronic non-infectious uveitis at Amiens-Picardie University Hospital.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
19 March 2025